| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $1,999,995 | 2 | 67 |
Sells | $292,776 | 1 | 33 |
| SEIDENBERG BETH C | director | 1 | $999,998 | 0 | $0 | $999,998 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 1 | $999,998 | 0 | $0 | $999,998 |
| Walker Karen Marie | Chief Technology Officer | 0 | $0 | 1 | $292,776 | $-292,776 |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Over the last 12 months, insiders at Kyverna Therapeutics, Inc. have bought $2M and sold $292,776 worth of Kyverna Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kyverna Therapeutics, Inc. have bought $11.01M and sold $292,776 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SEIDENBERG BETH C (director) — $999,998. Westlake BioPartners Opportunity Fund I, L.P. (10 percent owner) — $999,998.
The last purchase of 133,333 shares for transaction amount of $999,998 was made by Westlake BioPartners Opportunity Fund I, L.P. (10 percent owner) on 2025‑12‑18.
| 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 133,333 0.3262% | $7.50 | $999,998 | +20.14% | ||
| 2025-12-18 | SEIDENBERG BETH C | director | 133,333 0.3262% | $7.50 | $999,998 | +20.14% | ||
| 2025-12-15 | Sale | Walker Karen Marie | Chief Technology Officer | 23,998 0.0618% | $12.20 | $292,776 | -22.37% | |
| 2024-02-12 | GILEAD SCIENCES, INC. | 10 percent owner | 910,000 8.0369% | $22.00 | $20.02M | -75.24% |
| SEIDENBERG BETH C | director | 869317 1.4299% | $6.64M | 1 | 0 | |
| Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 869317 1.4299% | $6.64M | 1 | 0 | |
| Walker Karen Marie | Chief Technology Officer | 22636 0.0372% | $172,939.04 | 0 | 1 | |
| GILEAD SCIENCES, INC. | 10 percent owner | 4126119 6.7869% | $31.52M | 1 | 0 | <0.0001% |
$2,481,409 | 33 | 201.68% | $429M | |
$31,271,604 | 28 | 28.69% | $496.89M | |
$112,238,340 | 19 | 39.16% | $486.89M | |
$1,057,969 | 14 | 68.06% | $418.96M | |
$133,809,976 | 13 | 31.29% | $565.21M | |
$13,258,734 | 9 | 18.72% | $427.71M | |
$6,847,110 | 9 | 5.96% | $425.09M | |
$8,391,565 | 8 | 5.19% | $404.69M | |
$5,529,561 | 8 | 5.30% | $503.93M | |
$13,043,783 | 8 | 732.82% | $474.49M | |
$17,675,244 | 7 | 92.20% | $460.64M | |
$21,792,890 | 6 | 75.72% | $519.36M | |
$4,745,999 | 5 | -4.91% | $542.44M | |
$164,999,952 | 5 | -44.44% | $527.52M | |
$208,592 | 4 | 11.22% | $473.1M | |
$1,746,565 | 4 | -29.05% | $443.55M | |
$209,740 | 4 | -1.93% | $421.74M | |
Kyverna Therapeutics, Inc. Common Stock (KYTX) | $20,020,000 | 1 | -75.24% | $464.48M |
$3,850,000 | 1 | -51.32% | $451.32M |
| Increased Positions | 65 | +79.27% | 18M | +79.64% |
| Decreased Positions | 34 | -41.46% | 2M | -10.14% |
| New Positions | 36 | New | 15M | New |
| Sold Out Positions | 11 | Sold Out | 1M | Sold Out |
| Total Postitions | 113 | +37.8% | 39M | +69.5% |
| Vida Ventures Advisors, Llc | $39,675.00 | 7.94% | 4.52M | 0 | 0% | 2025-09-30 |
| Gilead Sciences, Inc. | $36,186.00 | 7.24% | 4.13M | 0 | 0% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $29,541.00 | 5.91% | 3.37M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $13,262.00 | 2.65% | 1.51M | -318,302 | -17.39% | 2025-09-30 |
| Vanguard Group Inc | $11,599.00 | 2.32% | 1.32M | +9,858 | +0.75% | 2025-09-30 |
| Insight Holdings Group, Llc | $8,674.00 | 1.74% | 989,054 | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $5,942.00 | 1.19% | 677,587 | -17,440 | -2.51% | 2025-09-30 |
| Mbb Public Markets I Llc | $5,389.00 | 1.08% | 614,477 | 0 | 0% | 2025-09-30 |
| Catalio Capital Management, Lp | $5,147.00 | 1.03% | 586,909 | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $4,838.00 | 0.97% | 551,635 | +99,075 | +21.89% | 2025-09-30 |